OTOBIOTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OTOBIOTIC (OTOBIOTIC).
Otobiotic is a fixed-dose combination of ciprofloxacin (a fluoroquinolone antibiotic) and fluocinolone acetonide (a corticosteroid). Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial DNA replication inhibition and cell death. Fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors, modulating gene expression, and reducing inflammatory mediators.
| Metabolism | Ciprofloxacin undergoes hepatic metabolism via CYP1A2 (minor pathway) and renal excretion (50-70% unchanged). Fluocinolone acetonide is metabolized in the liver via CYP3A4 and excreted in urine and feces. |
| Excretion | Renal elimination of unchanged drug: 60-80%; biliary/fecal elimination: 10-20%; the remainder undergoes hepatic metabolism. |
| Half-life | Terminal elimination half-life: 2-3 hours in patients with normal renal function; prolonged to 24-48 hours in anuria. |
| Protein binding | Plasma protein binding: 10-20%, primarily to albumin. |
| Volume of Distribution | Volume of distribution: 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid; low tissue penetration. |
| Bioavailability | Otic administration: locally high concentrations with negligible systemic absorption (<5%); systemic bioavailability is not clinically relevant for otic route. |
| Onset of Action | Otic administration: onset of antibacterial effect within 30 minutes; peak concentrations in ear fluids at 1-2 hours. |
| Duration of Action | Duration of action: 8-12 hours after otic administration, corresponding to sustained drug levels above MIC for common pathogens. |
| Molecular Weight | Neomycin B: 322.3 Da; Polymyxin B: 1303.5 Da; Hydrocortisone: 362.5 Da |
Adults and children: 3-4 drops into the affected ear twice daily for 7 days. Shake well before use.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Weight-based dosing not applicable; use age-based dosing: children (including infants) 3-4 drops twice daily for 7 days. |
| Geriatric use | No specific adjustment needed; follow adult dosing. |
| 1st trimester | Avoid use in first trimester due to potential ototoxicity and teratogenic risk unless clearly needed. |
| 2nd trimester | Use with caution; consider risk of fetal ototoxicity and nephrotoxicity. |
| 3rd trimester | Avoid use near term due to risk of neonatal ototoxicity and renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for OTOBIOTIC (OTOBIOTIC).
| Placental transfer | Crosses placenta; detectable in fetal serum and amniotic fluid. |
| Breastfeeding | Avoid breastfeeding during treatment; drug may be excreted in milk and cause ototoxicity or nephrotoxicity in infant. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to componentsPerforated tympanic membraneViral or fungal otic infections
| Precautions | Not for ophthalmic use or injection, Hypersensitivity reactions including anaphylaxis, Prolonged use may result in fungal or bacterial superinfection, Perforation of tympanic membrane: use with caution in patients with suspected or known perforation, Corticosteroid withdrawal symptoms with abrupt discontinuation after prolonged use |
| Food/Dietary | None known. Avoid alcoholic beverages during treatment due to potential for increased side effects (e.g., dizziness, sedation). |
| Clinical Pearls |
Loading safety data…
| L5 |
| Teratogenic Risk | First trimester: Cardiac and neural tube defects (ototoxic antibiotics). Second and third trimesters: Hearing loss, nephrotoxicity; avoid unless essential. |
| Fetal Monitoring | Audiometry, renal function tests, drug serum levels, fetal ultrasound. |
| Fertility Effects | May impair spermatogenesis; no evidence of female fertility effects. |
| Otic suspension; avoid touching tip to ear; warm bottle in hands before use; contraindicated in perforated tympanic membrane; shake well before each use; complete full course even if symptoms improve. |
| Patient Advice | Lie on side with affected ear up for 5 minutes after instillation. · Do not insert dropper tip into ear canal to avoid contamination. · Complete the prescribed duration even if feeling better. · Do not use if you have a perforated eardrum or ear tube. · Warm the bottle in your hands to avoid dizziness from cold liquid. · Shake the bottle well before each use. · Avoid getting the medication in your eyes. · Tell your doctor if you develop new ear drainage, pain, or rash. |